Combination hormone therapy for metastatic @entity0 . An ECOG study of megestrol and XXXX .

@entity1 @entity137 @entity0 @entity6 @entity101 @entity1910 @entity66 @entity16 @entity6239 @entity1017 @entity6303 @entity701 @entity4854
This study was performed to determine the @entity137 and effectiveness of @entity6303 used with @entity6239 - @entity701 in the treatment of @entity1 with metastatic @entity0 . Forty-five @entity1 were treated, 29 of whom were fully eligible. Twelve of the 45 who had @entity6 and/or @entity101 were also analyzed. All had measurable sites of disease. The median age was 63 years, and the median time from first recurrence to on-study was 19 months. Approximately half the @entity1 already had chemotherapy, and about 90% had hormone therapy for advanced disease. The most common side effects were @entity1910 , @entity1017 , @entity4854 , and @entity16 . No life-threatening or lethal @entity137 were reported. The overall response rate (complete or partial) among the fully eligible @entity1 was 34% (90% confidence intervals from 20% to 51%), with a 5-month median duration of response. @entity1 with soft tissue, visceral, and @entity66 responded. Seventy-two percent of fully eligible @entity1 have progressed or relapsed. The median time to failure of treatment was 6 months, and the median survival time was 15 months.
